Kytopen is a spin-out of MIT developing proprietary platforms for non-viral delivery of payloads for ex vivo cell therapy discovery and manufacturing. The scalable solution combines microfluidics and automation to make transfection easier, faster, and more cost-effective than the state-of-the art solutions. Kytopen is integrating their platforms with automated liquid handling systems for processing small volumes and also developing a large volume platform for therapeutic applications. The non-viral solution will accelerate the time-to-market of next-generation cell and gene therapies by enabling discovery of therapeutic targets and reducing the cell therapy manufacturing costs. Kytopen recently closed a $3.6 million seed funding round and is the recipient of a Phase II SBIR grant from the National Science Foundation (NSF).